AAX Biotech presenting Opti-mAb poster at Antibody Engineering & Therapeutics Europe

We are excited to share that AAX Biotech will attend the Antibody Engineering & Therapeutics Europe on 27-29 May at the Congress Center, Basel - one of Europe's leading conferences for the antibody engineering and therapeutics community.

Our CEO/CSO & Co-Founder, Daniel X Johansson, will be presenting a poster on Opti-mAb® - our cutting-edge technology that significantly improves the production yields and stability of scFv antibodies. Designed to solve one of the most persistent challenges in next-generation antibody therapeutics – scFv instability – Opti-mAb® reduces development costs and improves the therapeutic performance of next-generation modalities, such as bispecifics and CAR-Ts. 

Daniel will also be showcasing Seqitope®, our epitope mapping technology that is both high-resolution and high-throughput, allowing for faster antibody discovery and de-risked lead candidate selection. 

Find us at our poster: “Opti-mAb®: a novel scFv format for improved therapies.” 

Will you be in Basel? Let us know or connect directly with Daniel!